sparingvision.com

Our company

We are a biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases.
Our goal

Bringing innovative treatments to physicians and patients to address serious ocular disorders.
Press release

Tuesday, 11 May 2021 07:00

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SPVN20

About SPVN06

SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million people worldwide.

Retinitis pigmentosa

A group of inherited retinal diseases which are a leading cause of blindness globally.
Scientific Discovery

Over the last 20 years, the scientific founders of SparingVision have, with the support of other world leaders in the space, identified the relation between the survival of rods and the protection of cones, the latter being essential to preserve vision in retinitis pigmentosa patients.
Genomic Medicine

SparingVision’s lead product SPVN06 is a novel, mutation-agnostic gene therapy delivering the two synergetic isoforms of the NXNL1 gene (RdCVF and RdCVFL) into a single vector to treat patients who are experiencing degeneration of photoreceptors and partial loss of vision.

The Company’s second product, SPVN20, is another pioneering, mutation-agnostic gene therapy product which aims to restore visual acuity and color vision in advanced and late-stage Retinitis Pigmentosa (RP) patients with “dormant cones”, independently of their genetic mutation.

SPVN20

SparingVision’s second product, SPVN 20, is a pioneering gene therapy product obtained through the acquisition of Gamut Therapeutics in 2021. SPVN 20’s unique mutation-agnostic approach aims at...